CAMBRIDGE, Mass.–(BUSINESS WIRE)–EnClear Therapies, a medical device company focused on developing therapeutic systems that continuously clear toxic proteins from cerebrospinal fluids (CSF) for the treatment of neurological diseases, today announced that it has spun-out from QurAlis Corporation, a biotech company focused on developing precision therapeutics for ALS and other neurological diseases. EnClear’s mission …
Tag Archives: neurological diseases
December, 2018
April, 2018
-
20 April
Biogen Pays $1 Billion to Expand Partnership with Ionis to Develop Drugs for Various Neurological Diseases
CAMBRIDGE, Mass. & CARLSBAD, Calif.–(BUSINESS WIRE)–Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals (Nasdaq: IONS) announced today they have expanded their strategic collaboration through a new ten-year collaboration agreement to develop novel antisense drug candidates for a broad range of neurological diseases. This collaboration capitalizes on Biogen’s expertise in neuroscience research and drug …
March, 2017
-
17 March
AveXis’ Gene Therapy for SMA Demonstrates Positive Results
CHICAGO, March 16, 2017 (GLOBE NEWSWIRE) — AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today reported topline results from the Phase 1 trial of AVXS-101 in spinal muscular atrophy (SMA) Type 1. The company also reported financial …
January, 2017
-
18 January
Takeda and Ovid Partner for Development of Rare Pediatric Epilepsy Drug
OSAKA, Japan & NEW YORK–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE: 4502) and Ovid Therapeutics Inc., a privately-held biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced the formation of a global collaboration focused on the clinical development and commercialization of Takeda’s …
April, 2015
-
17 April
FDA Asks Genervon to Release Complete Data from Controversial ALS Study
The US Food and Drug Administration (FDA) issued a statement calling on Genervon Biopharmaceuticals to release complete data from their recent trial evaluating an experimental drug for treatment of amyotrophic lateral sclerosis (ALS). The agency is prohibited by law from releasing confidential information about experimental drugs, however the agency requested …